Share

October 2021; 11 (5) Research

Impact of ICD-9 to ICD-10 Coding Transition on Prevalence Trends in Neurology

Ali G. Hamedani, Leah Blank, Dylan P. Thibault, Allison W. Willis
First published January 29, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001046
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
77

Share

Article Information

vol. 11 no. 5 e612-e619
DOI: 
https://doi.org/10.1212/CPJ.0000000000001046
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received June 19, 2020
  • Accepted October 28, 2020
  • First Published January 29, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Ali G. Hamedani, MD, MHS,
    2. Leah Blank, MD, MPH,
    3. Dylan P. Thibault, MS and
    4. Allison W. Willis, MD, MSCI
  1. Ali G. Hamedani, MD, MHS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board member for CONTINUUM: Lifelong Learning in Neurology, 2017-2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NINDS T32 NS061779-10 (2018-2010)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Parkinson Study Group Mentored Clinical Research Award (2019-2020)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Leah Blank, MD, MPH,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Pharmacoepidemiology Training Grant (T32-GM-075766)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) American Epilepsy Society / Epilepsy Foundation Junior Investigator Award (2) American Epilepsy Society/ New-onset refractory status epilepticus (NORSE) Foundation seed fund (3) Mirowski Family Fund

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) Bristol Myers Squibb, spouse employed by a multinational law firm of whom BMS was a client in 2018- 2020.

  3. Dylan P. Thibault, MS and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Allison W. Willis, MD, MSCI
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I have been an associate editor for the journal Pharmacoepidemiology and Drug Safety in August 2013.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Commercial. I am a site-investigator for an international multicenter clinical trial of a investigational drug for the treatment of Parkinson disease

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health/NINDS, R01 ns099129 Principle Investigator, September 2017- present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology and Translational Center of Excellence for Neuroepidemiology and Neurology Outcomes Research (AGH, DPT), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Departments of Neurology and Population Health Science and Policy (LB), Icahn School of Medicine at Mount Sinai, New York; and Departments of Neurology and of Biostatics and Epidemiology and Translational Center of Excellence for Neuroepidemiology and Neurology Outcomes Research (AWW), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  1. Correspondence
    Dr. Hamedani ali.hamedani{at}pennmedicine.upenn.edu
View Full Text

Article usage

Article usage: January 2021 to July 2022

AbstractFullPdfSource
Jan 20211401Highwire
Feb 202117206Highwire
Mar 202110206Highwire
Apr 202195010Highwire
May 20215602Highwire
Jun 20216303Highwire
Jul 20213805Highwire
Aug 20214204Highwire
Sep 20213101Highwire
Oct 2021158107Highwire
Nov 2021208117Highwire
Dec 202115958Highwire
Jan 20226831Highwire
Feb 20228433Highwire
Mar 20229224Highwire
Apr 20227875Highwire
May 20227921Highwire
Jun 20226800Highwire
Jul 20226023Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me